

## EARLY CLINICAL TRIALS EXPERTISE

### ORAL & POSTER PRESENTATIONS

#### EORTC-NCI-AACR 2016

- First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies (poster)

#### ESMO ASIA 2015

- First-in-human study of oral S 49076, a MET/AXL/FGFR inhibitor, in advanced solid tumors (poster discussion)

#### ECCO-ESMO 2013

- Towards new methods for the determination of Dose Limiting Toxicities and Recommended Dose of Molecularly Targeted Agents

### PUBLICATIONS

- Infante JR, Hollebecque A, **Postel-Vinay S**, Bauer TM, Blackwood E, Evangelista M, Mahrus S, Peale F, Lu X, Sahasranaman S, Zhu R, Chen Y, Ding X, Murray E, Schutzman J, Lauchle JO, Soria JC, LoRusso PM. Phase I Study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors. *Clin Cancer Res.* 2017 May 15;23(10):2423-2432.
- **Postel-Vinay S**, Aspeslagh S, Lanoy E, Robert C, Soria JC, Marabelle A. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. *Ann Oncol.* 2016;27(2):214-224.
- **Postel-Vinay S**, Boursin Y, Massard C, Hollebecque A, Ileana E, Chiron M, Jung J, Lee JS, Balogh Z, Adam J, Vielh P, Angevin E, Lacroix L, Soria JC. Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing? *Ann Oncol.* 2016;27(2):344-52.
- Dercle L, Ammari S, Champiat S, Massard C, Ferte C, Taihi L, Seban RD, Aspeslagh S, Mahjoubi L, Kamsu-Kom N, Robert C, Marabelle A, Schlumberger M, Soria JC, **Postel-Vinay S**. Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy. *Eur J Cancer.* 2016;65:33-42.
- Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, **Postel-Vinay S**, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. *Lancet Oncol.* 2017 Dec;18(12):1590-1599.
- Rodon J, **Postel-Vinay S**, Hollebecque A, Nuciforo P, Azaro A, Cattani V, Marfai L, Sudey I, Brendel K, Delmas A, Malasse S, Soria JC. First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. *Eur J Cancer* 2017. 81:142-150.



Sophie Postel-Vinay

MD  
PhD

## General background

Sophie Postel-Vinay (MD, Ph.D), is currently Physician Scientist at the Drug Development Department and U981 INSERM research unit of Gustave Roussy Cancer Campus, where she leads an independent research group as of January 2018 thanks to the ATIP-Avenir INSERM/CNRS grant.

She received her medical degree from the Université René Descartes Paris V in 2010, and joined the faculty in November 2013 after completion of her PhD. She completed her residency training in Paris, and spent 18 months at the Royal Marsden Hospital of London in Pr Stan Kaye Drug Development Unit. Dr Postel-Vinay is member of AACR and ASCO, from which she received a merit award in 2010. She is also an ESMO member, has been representative of the French Young Oncologist at the Young Oncologists Committee from 2013-2016, and received the ESMO translational research fellowship for her PhD that was performed at the Institute of Cancer Research (London) in Pr Alan Ashworth laboratory, focusing on DNA repair and synthetic lethality.

Dr Postel-Vinay has a physician scientist position since 2016, which allows her to have a fundamental research activity within the INSERM Unit 981 (80% of her time), in parallel of her clinical drug development activity (phase 1 trials). She obtained in 2017 the ATIP-Avenir "Young Group Leader" grant from INSERM/CNRS, which now allows her to develop her own group as an independent research team. Her research activity focuses on chromatin remodeling and its interplay with DNA damage repair and immune modulation in solid tumor cancer models. Her research interests include DNA repair, chromatin remodeling and synthetic lethality, sarcoma, drug development, predictive biomarkers and emerging targets.